2024-10-16 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis Report

**Company Overview:** Amgen Inc. is a leading biotechnology company developing and delivering innovative human therapeutics.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (AMGN):** 83.62%
* **Cumulative Return (VOO):** 135.82%
* **Performance Difference:** -52.2%
* **Relative Divergence:** 33.78% 

This signifies that AMGN has underperformed VOO by 52.2% in cumulative returns.  However, its relative divergence of 33.78% suggests that it has been performing within the historical range of performance differences between AMGN and VOO.

**2. Recent Price Action:**

* **Closing Price:** 328.35
* **5-Day Moving Average:** 321.38
* **20-Day Moving Average:** 325.42
* **60-Day Moving Average:** 327.48

The stock is currently trading above its 5-day, 20-day, and 60-day moving averages, suggesting a potential upward trend. 

**3. Technical Indicators:**

* **RSI:** 44.49 
* **PPO:** 0.05
* **Delta_Previous_Relative_Divergence:** -9.01 (indicating a recent short-term downtrend)
* **Expected_Return:** 0.0% (estimated maximum 5-year expected return over VOO)

The RSI suggests a neutral sentiment, while the PPO indicates slight positive momentum. The recent short-term downtrend may warrant further observation. 

**4. Recent Earnings and Outlook:**

| Date      | EPS        | Revenue       |
|-----------|-------------|---------------|
| 2024-08-07 | 1.39       | 8.39 B$       |
| 2024-05-03 | -0.21      | 7.45 B$       |
| 2023-10-31 | 3.23       | 6.90 B$       |
| 2023-08-04 | 2.58       | 6.99 B$       |
| 2024-08-07 | 2.58       | 6.99 B$       |

The most recent earnings release (2024-08-07) showed a positive EPS of 1.39, exceeding analyst expectations. The company's revenue also surpassed expectations, indicating strong financial performance. The company's future outlook remains positive, with continued growth in key areas like its oncology portfolio.

**5. News and Recent Issues:**

**Recent Market Outlook for AMGN:**

* AMGN's recent earnings beat has boosted investor confidence. 
* The company's robust pipeline and focus on innovation are considered growth drivers.
* Concerns remain regarding potential competition in the biosimilar market.

**Analyst Opinions and Performance Highlights:**

* FINBOLD provides a positive outlook for AMGN, highlighting its strong market position and potential for future growth.
* Several analysts have upgraded their ratings on AMGN, reflecting confidence in the company's long-term prospects.
*  The stock is currently trading near its 52-week high, suggesting a positive market sentiment.

**6. Overall Analysis:**

Amgen Inc. (AMGN) is a well-established biotechnology company with a strong track record and a promising future. While the stock has underperformed the S&P 500 in the past, it remains a solid investment option with potential for growth. The company's recent earnings beat and positive market sentiment suggest a positive outlook. 

**7. Recommendations:**

* Investors looking for a long-term growth stock in the biotechnology sector should consider AMGN. 
* However, it's important to monitor the company's progress and market trends to make informed investment decisions.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Consult with a financial professional before making any investment decisions.
